Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NERA: Neoadjuvant Erdafitinib +/- Atezolizumab in MIBC
NCT05564416Phase 2Withdrawn
- Sponsor
- National Cancer Institute
- Start
- Oct 2023
- Primary completion
- Jan 2024
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of erdafitinib in muscle-invasive bladder cancer (MIBC), sponsored by National Cancer Institute. Planned start Oct 2023; status: withdrawn.
02
Drugs
erdafitinib
03
Conditions
muscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on NCT05564416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05564416.